Amend Surgical

Amend Surgical is a clinical-stage medical device company pioneering novel adhesive and barrier technologies for regenerative medicine and surgical applications. Its core platform leverages biocompatible hydrogel and chitosan-based formulations to create strong, lasting adhesion in wet, mechanically demanding environments like the oral cavity and peripheral nerves. While its NanoFUSE implant is commercially available for bone fusion, the company's near-term focus is advancing its pre-market products, Amend Tissue Tape for oral wound care and Tissure for suture-less nerve repair, through regulatory milestones and eventual launch. The company is backed by founder/family equity and non-dilutive grants, operating from its base in Alachua, Florida.

Bio-inspired adhesive platform utilizing biocompatible hydrogels and chitosan-based formulations to create strong, long-lasting adhesion and barrier protection in wet, mechanically challenging surgical environments. The platform supports non-resorbable and resorbable barriers with potential for targeted drug delivery.

Amend Surgical competes in crowded markets. In dental wound care, it faces established tissue sealants and hemostats from companies like Baxter and Integra LifeSciences. In nerve repair, it competes with suture manufacturers and emerging nerve wrap technologies. Its bone graft product, NanoFUSE, competes with a wide array of synthetic and allograft products from giants like Stryker, Medtronic, and Zimmer Biomet.